Dr. Ari Melnick led a team of national and international scientists in a first of its kind study in which they decoded the key "software" instructions that drive three of the most virulent forms of acute lymphoblastic leukemia (ALL). Specifically, they uncovered that ALL's "software" is encoded with epigenetic marks, chemical modifications of DNA and surrounding proteins, allowing the research team to identify new potential biomarkers and therapeutic targets.
Established by the National Academy of Sciences in 1970, the IOM has 1,928 members with selection based on a record of making major contributions to the advancement of medical sciences, health care, and public health.
The ASH Clinical Research Training Institute is a "year-long education and mentoring program for hematology fellows and junior faculty at academic medical centers and offers a broad education about clinical research methods, research collaborations, statistical analysis, and managing the demands of family and career."
Dr. Linda Vahdat, Director of the Breast Cancer Research Program and Chief of the Solid Tumor Service, Division of Hematology & Medical Oncology, was featured in a MSNBC report on Halaven, a new drug for treating metastatic breast cancer. Halaven is derived from the sea sponge.
Dr. Leandro Cerchietti has received a Doris Duke Clinical Scientist Development Award (one of only 12 such awards given yearly by the Doris Duke Foundation). Funding is $150,000 per year spanning 3 years; his project centers on the role of metabolism in determining the clinical behavior of tumors, using metabolomic profiling for the study of B-cell lymphoma.
Dr. Gail J. Roboz is physician to ABC Good Morning America anchor Robin Roberts. She treated Ms. Roberts who has MDS, or myelodysplastic syndrome, a disorder of the stem cells in bone marrow that impairs blood production.
The 2012 Department of Medicine Investigator Award finalists were announced and their talks were delivered during Grand Rounds on May 22, 2012. This was the 21st annual presentation of the DOM Investigator Award, which is presented to members of the Department of Medicine, below the rank of professor, who perform on an outstanding level in the areas of clinical and/or basic biomedical research. The award is generously supported by the Michael Wolk Foundation.
Dr. Ari Melnick and colleagues have received a multi-investigator collaborative grant from the National Cancer Institute in support of clinical trials for the treatment of cancer; this, following their most recent discovery involving a tumor-targeting compound known as PU-H71, which was published in Nature Chemical Biology.
The paper published in Cancer Discovery identifies a new molecular target for this lethal subtype of prostate cancer for which there is currently a drug available. Specifically, Drs. Beltran and Rubin have discovered that the aurora kinase inhibitor PHA-739358 works against human neuroendocrine prostate cells.
Located on Floor 12 of the Weill Greenberg Ambulatory Building, 1305 York Avenue, the stunningly attractive facilities represent state-of-the-art patient care at its best. Individual treatment bays are equipped with flat screen televisions and provide sweeping views of York Avenue.
